GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Forward PE Ratio

Kyorin Pharmaceutical Co (TSE:4569) Forward PE Ratio : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Forward PE Ratio?

Kyorin Pharmaceutical Co's Forward PE Ratio for today is 0.00.

Kyorin Pharmaceutical Co's PE Ratio without NRI for today is 19.27.

Kyorin Pharmaceutical Co's PE Ratio for today is 18.21.


Kyorin Pharmaceutical Co Forward PE Ratio Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Forward PE Ratio Chart

Kyorin Pharmaceutical Co Annual Data
Trend
Forward PE Ratio

Kyorin Pharmaceutical Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Kyorin Pharmaceutical Co's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Forward PE Ratio falls into.



Kyorin Pharmaceutical Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Kyorin Pharmaceutical Co  (TSE:4569) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Kyorin Pharmaceutical Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines